Presentation is loading. Please wait.

Presentation is loading. Please wait.

When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer.

Published byElaine Patterson Modified over 5 years ago

Similar presentations

Presentation on theme: "When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer."— Presentation transcript:

1 When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer Who Have Received Neoadjuvant Chemoradiotherapy?  Robert James Cerfolio, MD, Ayesha S. Bryant, MSPH, MD  The Annals of Thoracic Surgery  Volume 84, Issue 4, Pages (October 2007) DOI: /j.athoracsur Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Algorithm for the restaging of patients with stage IIIa (N2) non-small cell lung cancer after neoadjuvant chemoradiotherapy using cisplatinum-based chemotherapy and concurrent high dose (60 Gy or greater) of radiotherapy. (CT = computed tomography; maxSUV = maximum standardized uptake value; PET = positron emission tomography.) The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Accuracy of integrated 2-fluoro-2-deoxy-d-glucose positron emission tomography (PET)/computed tomography scan for restaging, overall (gray bars) and for N2 disease (black bars) based on the time interval between the last dose of radiotherapy and the repeat PET scan. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Receiver operating characteristic curve (black line) with 95% confidence intervals (gray lines) shows the optimal time to perform a repeat positron emission tomography scan after neoadjuvant chemoradiotherapy therapy for overall staging, which was 26 days after last dose of radiotherapy (area under the curve, diagonal line, 0.88). The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Receiver operating characteristic curve (black line) with 95% confidence intervals (gray lines) shows the optimal time to perform a repeat positron emission tomography scan after neoadjuvant chemoradiotherapy for N2 restaging, which was 29 days after the last dose of radiotherapy (area under the curve, diagonal line, 0.82). All 97 patients with IIIa (N2) disease had biopsy-proven N2 nodes and then underwent rebiopsy or removal of the same node after neoadjuvant therapy. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2007 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "When is it Best to Repeat a 2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Scan on Patients with Non-Small Cell Lung Cancer."

Similar presentations

Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer  Nadya Shusharina, PhD,

Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer  Nadya Shusharina, PhD,
Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E
Photodynamic Laser Therapy for Lesions in the Airway

Photodynamic Laser Therapy for Lesions in the Airway
Endoscopic Ultrasound-Guided Fine Needle Aspiration of Mediastinal Lymph Node in Patients With Suspected Lung Cancer After Positron Emission Tomography.

Endoscopic Ultrasound-Guided Fine Needle Aspiration of Mediastinal Lymph Node in Patients With Suspected Lung Cancer After Positron Emission Tomography.
Elizabeth A. David, MD, David T

Elizabeth A. David, MD, David T
Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L
Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes  Meng S. Shao, MD, Andrew T. Wong, MD,
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Endobronchial Ultrasonography for Positron Emission Tomography and Computed Tomography–Negative Lymph Node Staging in Non-Small Cell Lung Cancer  Masato.

Endobronchial Ultrasonography for Positron Emission Tomography and Computed Tomography–Negative Lymph Node Staging in Non-Small Cell Lung Cancer  Masato.
Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer
Ravi Rajaram, MD, MSc, Jennifer L

Ravi Rajaram, MD, MSc, Jennifer L
Phillips B. Harrington, MD, William W. McAlexander, MD, Ayesha S

Phillips B. Harrington, MD, William W. McAlexander, MD, Ayesha S
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
A Nondivided Intercostal Muscle Flap Further Reduces Pain of Thoracotomy: A Prospective Randomized Trial  Robert James Cerfolio, MD, Ayesha S. Bryant,

A Nondivided Intercostal Muscle Flap Further Reduces Pain of Thoracotomy: A Prospective Randomized Trial  Robert James Cerfolio, MD, Ayesha S. Bryant,
Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes  Julie E. Bauman, MD, Michael.
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Cooperative Group Clinical Trials in General Thoracic Surgery: Report From the 2012 Robert Ginsberg Clinical Trials Meeting of the General Thoracic Surgical.

Cooperative Group Clinical Trials in General Thoracic Surgery: Report From the 2012 Robert Ginsberg Clinical Trials Meeting of the General Thoracic Surgical.

Similar presentations

Ads by Google